Related Experiment Video
Updated: May 23, 2026

Flow-sorting and Exome Sequencing of the Reed-Sternberg Cells of Classical Hodgkin Lymphoma
Published on: June 10, 2017
Hodgkin Lymphoma: Management of Patients Who Fail Primary Therapy
Kento Kawai1, Neha Akkad2, Christopher Flowers3
1Baylor School of Medicine, Internal Residency Program, Houston, TX.
Abstract:
Management of relapsed/refractory (R/R) classic Hodgkin lymphoma (cHL) has evolved substantially with the integration of novel targeted and immune-based therapies. Agents such as brentuximab vedotin (BV) and immune checkpoint inhibitors (CPIs) have demonstrated high response rates in multiple settings and are increasingly used as therapeutic strategies for frontline, salvage, and multiply relapsed cHL. Consequently, the traditional roles of cytotoxic chemotherapy and stem cell transplantation are being redefined, with greater emphasis on disease biology and individualized risk-benefit assessment. Though data are continuing to evolve, it appears that the use of CPIs and BV can improve outcomes for patients with R/R disease, even as retreatment, and can lead to durable remissions. This review summarizes current management paradigms for R/R cHL and highlights emerging data regarding sequencing, retreatment, and the use of novel agents.
Related Concept Videos
Treatment Resistant Cancers
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Tumor Immunotherapy
Treatment Resistent Cancers
Primary Lymphoid Organs
The red bone marrow is a soft, spongy tissue nestled in the interior of long bones such as the humerus and femur. It is the site...
Heart Failure VI: Adjunct Therapies